Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H16BrNO2.ClH |
| Molecular Weight | 346.647 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(OC(=C2)C3CCNCC3)C(Br)=C1
InChI
InChIKey=PUYKEOGYPYITCW-UHFFFAOYSA-N
InChI=1S/C14H16BrNO2.ClH/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11;/h6-9,16H,2-5H2,1H3;1H
| Molecular Formula | C14H16BrNO2 |
| Molecular Weight | 310.186 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) developed by Ciba-Geigy for depression and anxiety disorders treatment. Brofaromine induces short, reversible and selective inhibition of brain MAO of type A in a dose-dependent manner in all brain regions. The largest decrease being found respectively in hippocampus, striatum and prefrontal cortex, regions having a rich monoaminergic innervation. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones. | 2011-12-08 |
|
| Brain serotonergic and dopaminergic modulators, perceptual responses and endurance exercise performance following caffeine co-ingested with a high fat meal in trained humans. | 2010-05-27 |
|
| Management of anorexia and bulimia nervosa: An evidence-based review. | 2010-04 |
|
| Post-traumatic stress disorder. | 2010-02-03 |
|
| Brain serotonin and dopamine modulators, perceptual responses and endurance performance during exercise in the heat following creatine supplementation. | 2008-09-30 |
|
| Pharmacotherapy of panic disorder. | 2008-08 |
|
| Post-traumatic stress disorder. | 2007-08-01 |
|
| Transdermal selegiline for the treatment of major depressive disorder. | 2007 |
|
| Traumatic stress: effects on the brain. | 2006 |
|
| Fluvoxamine in the treatment of anxiety disorders. | 2005-12 |
|
| Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors. | 2005-06-30 |
|
| SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. | 2004-09 |
|
| Pre- and post-treatment with pirlindole and dehydropirlindole protects cultured brain cells against nitric oxide-induced death. | 2003-04-11 |
|
| Antidepressants versus placebo for people with bulimia nervosa. | 2003 |
|
| Pharmacotherapy of social phobia. | 2003 |
|
| Pharmacological treatment of social anxiety disorder: a meta-analysis. | 2003 |
|
| Psychopharmacology of anxiety disorders. | 2002-09 |
|
| Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition. | 2002-02 |
|
| Pharmacotherapy of social anxiety disorder. | 2002-01-01 |
|
| Antidepressants in social anxiety disorder. | 2001-09 |
|
| Predictors of treatment response in patients with posttraumatic stress disorder. | 2001-02 |
|
| Antidepressants versus placebo for people with bulimia nervosa. | 2001 |
|
| Treatment of social phobia with antidepressants. | 2001 |
|
| A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. | 1996-08 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:08:53 GMT 2025
by
admin
on
Mon Mar 31 18:08:53 GMT 2025
|
| Record UNII |
Z1JJCCZX3P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
63638-90-4
Created by
admin on Mon Mar 31 18:08:53 GMT 2025 , Edited by admin on Mon Mar 31 18:08:53 GMT 2025
|
PRIMARY | |||
|
DTXSID10979854
Created by
admin on Mon Mar 31 18:08:53 GMT 2025 , Edited by admin on Mon Mar 31 18:08:53 GMT 2025
|
PRIMARY | |||
|
44570
Created by
admin on Mon Mar 31 18:08:53 GMT 2025 , Edited by admin on Mon Mar 31 18:08:53 GMT 2025
|
PRIMARY | |||
|
Z1JJCCZX3P
Created by
admin on Mon Mar 31 18:08:53 GMT 2025 , Edited by admin on Mon Mar 31 18:08:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
